Comparative Pharmacology
Head-to-head clinical analysis: BIMZELX versus LATISSE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BIMZELX versus LATISSE.
BIMZELX vs LATISSE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
BIMZELX (bimekizumab) is a humanized monoclonal IgG1 antibody that selectively neutralizes interleukin-17A (IL-17A) and interleukin-17F (IL-17F), inhibiting their binding to the IL-17 receptor and subsequent pro-inflammatory signaling.
Bimatoprost is a synthetic prostamide analog that selectively mimics the effects of prostamide F2α. It increases the growth of eyelashes by prolonging the anagen (growth) phase and increasing the number of hairs. The exact molecular mechanism is thought to involve binding to prostamide receptors, leading to modulation of intracellular signaling pathways that regulate hair follicle cycling.
Subcutaneous injection: 160 mg (two 80 mg injections) at week 0, week 2, week 4, then every 4 weeks.
One drop applied to the upper eyelid margin at the base of the eyelashes once daily using the provided sterile applicators.
None Documented
None Documented
Terminal elimination half-life is approximately 26 days (range 22–29 days) across approved doses; supports every 4-week subcutaneous dosing.
The terminal elimination half-life of bimatoprost in plasma is approximately 45 minutes (range 30-60 minutes) after topical ocular application in humans. This short half-life reflects rapid systemic clearance, but the drug's ocular hypotensive effect persists for 24 hours due to tissue binding.
Bimekizumab is a monoclonal antibody that is degraded into small peptides and amino acids via general protein catabolism; no renal or biliary excretion of intact antibody. Fecal excretion of degraded fragments is minor (<1%).
Primarily renal elimination of metabolites; less than 5% of unchanged bimatoprost is excreted in urine. Fecal excretion accounts for approximately 25% of the dose, predominantly as metabolites. Biliary excretion is minimal.
Category C
Category C
Prostaglandin Analog
Prostaglandin Analog